Roth Capital Keeps Prima BioMed (PBMD) at 'Buy' Following Receipt of IMP731-Related European Patent

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Roth Capital Keeps Prima BioMed (PBMD) at 'Buy' Following Receipt of IMP731-Related European Patent

European Patent Grants for IMP731 Antibody

August 24, 2016 8:36 PM EDT

SYDNEY, AUSTRALIA -- (Marketwired) -- 08/24/16 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 2142210 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the European Patent Office.

The patent relates to Prima's IMP731 antibody (originally developed by Immutep SAS). The granted... More